{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T09:24:47Z","timestamp":1790501087557,"version":"4.1.0"},"reference-count":20,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T00:00:00Z","timestamp":1627257600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Virology"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Objective: To systematically evaluate the effectiveness and safety of the SARS\u2010CoV\u20102 vaccines currently undergoing clinical trials. Methods: PubMed, EMBASE,\u00a0and Cochrane Library databases\u00a0were searched to collect open human COVID\u201019 vaccines randomized controlled trials, without limiting the search time and language. The research papers collected in the above\u2010mentioned databases\u00a0were initially screened according to the title and abstract content and merged, and the repeated ones\u00a0were removed. After reading the full text of the remaining research, the studies that did not meet the inclusion criteria were excluded, and finally, nine studies were obtained. After extracting the statistical data of adverse events in the study, load them into Review Manager for heterogeneity analysis. Results: The incidence of adverse reactions of inactivated virus vaccines, RNA vaccines, and adenovirus vector vaccines was higher than that of placebo. Common adverse reactions included pain, swelling, and fever at the injection site. Conclusion: From the perspective of effectiveness, RNA vaccine\u2009&gt;\u2009adenovirus vector vaccine\u2009&gt;\u2009inactivated virus vaccine.\u00a0From the perspective of safety, the incidence of adverse reactions of the three vaccines is higher than that of a placebo, and the incidence of adverse reactions of the adenovirus vector vaccine is higher.<\/jats:p>","DOI":"10.1002\/jmv.27203","type":"journal-article","created":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T13:20:10Z","timestamp":1626355210000},"page":"6486-6495","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["Safety and effectiveness of SARS\u2010CoV\u20102 vaccines: A systematic review and meta\u2010analysis"],"prefix":"10.1002","volume":"93","author":[{"given":"Yunzhi","family":"Ling","sequence":"first","affiliation":[{"name":"Department of Infectious Disease, Center Lab of Longhua Branch, Shenzhen People's Hospital, The Second Clinical Medical College, Jinan University, The First Affiliated Hospital Southern University of Science and Technology  Shenzhen Guangdong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaying","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Research Center Algae Company  Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaru","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Research Center Algae Company  Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,7,26]]},"reference":[{"key":"e_1_2_6_2_1","unstructured":"World Health Organization. Draft landscape and tracker of COVID\u201019 candidate vaccines.https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines.2021."},{"key":"e_1_2_6_3_1","unstructured":"China grants conditional approval for first COVID vaccine.http:\/\/english.nmpa.gov.cn\/2020-12\/31\/c_579192.htm.2020."},{"key":"e_1_2_6_4_1","unstructured":"NMPA conditionally approves COVID\u201019 vaccine developed by Sinopharm's Wuhan Institute.http:\/\/english.nmpa.gov.cn\/2021-02\/27\/c_597152.htm.2021."},{"key":"e_1_2_6_5_1","unstructured":"Sinovac COVID\u201019 vaccine granted conditional market approval in China.http:\/\/english.nmpa.gov.cn\/2021-02\/07\/c_588422.htm.2021."},{"key":"e_1_2_6_6_1","unstructured":"Pfizer and BioNTech Receive authorization in the European Union for COVID\u201019 vaccine.https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-and-biontech-receive-authorization-european-union.2020."},{"key":"e_1_2_6_7_1","unstructured":"CanSinoBIO Announces Approval for its Single\u2010Dose COVID\u201019 Vaccine in China.http:\/\/www.cansinotech.com\/html\/1\/\/\/179\/180\/654.html.2021."},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000100"},{"key":"e_1_2_6_9_1","first-page":"ED000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"10","author":"Cumpston M","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2035389"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2639-4"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2034577"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2034201"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1473?3099(20)30987?7"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.15543"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1473?3099(20)30831?8"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1473?3099(20)30843?4"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140?6736(20)31605?6"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00352-y"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00594"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.02130"}],"container-title":["Journal of Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.27203","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jmv.27203","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.27203","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T23:24:55Z","timestamp":1693005895000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmv.27203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,26]]},"references-count":20,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1002\/jmv.27203"],"URL":"https:\/\/doi.org\/10.1002\/jmv.27203","archive":["Portico"],"relation":{},"ISSN":["0146-6615","1096-9071"],"issn-type":[{"value":"0146-6615","type":"print"},{"value":"1096-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,26]]},"assertion":[{"value":"2021-07-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}